Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 4/20 | 0.46 |
| ▸ | BACE1 | P56817 | 4/20 | 0.46 |
| ▸ | BCHE | P06276 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4048096 | 0.92 | LTA4H (0.53) | LTA4HACHEBACE1BCHEPKM | |
| SCHEMBL4289743 | 0.89 | LTA4H (0.49) | LTA4HACHEBACE1BCHEALDH1A1 | |
| SCHEMBL4292943 | 0.84 | HTT (0.47) | LTA4HPOLBLMNAACHEBACE1 | |
| SCHEMBL4284816 | 0.84 | ACHE (0.48) | LTA4HLMNAACHEBACE1BCHE | |
| SCHEMBL4287399 | 0.84 | LTA4H (0.48) | LTA4HPOLBACHEBACE1BCHE | |
| SCHEMBL4289616 | 0.84 | LTA4H (0.48) | LTA4HPOLBACHEBACE1BCHE | |
| SCHEMBL8123690 | 0.84 | LTA4H (0.52) | LTA4HPOLBLMNAACHEBACE1 | |
| SCHEMBL4287262 | 0.83 | LTA4H (0.47) | LTA4HPOLBACHEBACE1BCHE | |
| SCHEMBL4294444 | 0.82 | ACHE (0.48) | LTA4HLMNAACHEBACE1BCHE | |
| SCHEMBL4289865 | 0.82 | LTA4H (0.45) | LTA4HLMNAACHEBACE1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | LTA4H 1197/4885POLB 3799/4885LMNA 1785/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | LTA4H 1197/4885POLB 3799/4885LMNA 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.